The effect of PPI use on human gut microbiota and weight loss in patients undergoing laparoscopic Roux-en-Y gastric bypass

Emily K. Ward, Dara P. Schuster, Katie H. Stowers, Amanda K. Royse, Diana Ir, Charles E. Robertson, Daniel N. Frank, Gregory L. Austin

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Laparoscopic Roux-en-Y gastric bypass (LRYGB) achieves sustainable weight loss possibly by altering the gut microbiota. The effect of a proton pump inhibitor (PPI) on weight loss and the gut microbiota has not been explored. PPI use and the gut microbiota were assessed before and 6 months after LRYGB in eight patients. Bacterial profiles were generated by 16S ribosomal RNA (rRNA) gene sequencing. Prior to LRYGB, PPI users had a higher percent relative abundance (PRA) of Firmicutes compared to nonusers. PPI users at 6 months post-LRYGB had a higher PRA of Firmicutes [48.6 versus 35.6 %, p=nonsignificant (NS)] and a trend toward significantly lower percent excess weight loss (49.3 versus 61.4 %, p=0.067) compared to nonusers. PPI use post-LRYGB may impair weight loss by modifying gut microbiota.

Original languageEnglish (US)
Pages (from-to)1567-1571
Number of pages5
JournalObesity Surgery
Volume24
Issue number9
DOIs
StatePublished - Sep 2014
Externally publishedYes

Keywords

  • Gastric bypass
  • Gut microbiota
  • PPI
  • Severe obesity

ASJC Scopus subject areas

  • Surgery
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Fingerprint

Dive into the research topics of 'The effect of PPI use on human gut microbiota and weight loss in patients undergoing laparoscopic Roux-en-Y gastric bypass'. Together they form a unique fingerprint.

Cite this